The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
BLU-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advanced EGFR-mutant (EGFRm) NSCLC in the phase 1/2 SYMPHONY study.
 
Yasir Y Elamin
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Medarex; Lilly; Sanofi; Spectrum Pharmaceuticals; Takeda; Turning Point Therapeutics
Research Funding - AstraZeneca; Blueprint Medicines; Elevation Oncology; Forward; Lilly; Precision Therapeutics; Spectrum Pharmaceuticals; Takeda; Turning Point Therapeutics; Xcovery
Travel, Accommodations, Expenses - Lilly
 
Misako Nagasaka
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Daiichi Sankyo; EMD Serono; Genentech; Janssen; Lilly; Mirati Therapeutics; Novartis; Pfizer; Takeda
Speakers' Bureau - Blueprint Medicines; Janssen; Mirati Therapeutics; Mirati Therapeutics; Takeda
Research Funding - Tempus
Travel, Accommodations, Expenses - Anheart Therapeutics
 
Elaine Shum
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Genentech; Janssen
Research Funding - Delfi Diagnostics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Nektar
 
Lyudmila Bazhenova
Stock and Other Ownership Interests - Epic Sciences
Consulting or Advisory Role - Abbvie; Bayer; Daichi; Elevation Oncology; Genentech/Roche; InterVenn Biosciences; Johnson and Johnson; Merck; Mirati Therapeutics; neuvogen; Novocure; ORCIC; Regeneron; Sanofi; Turning Point Therapeutics
 
D. Ross Camidge
Honoraria - Abbvie; Amgen Astellas BioPharma; Anheart Therapeutics; Apollomics; AstraZeneca; BeiGene; BeiGene; bio-thera; Daiichi Sankyo; Dizal Pharma; Elevation Oncology; EMD Serono; Helsinn Therapeutics; Hengrui Pharmaceutical; Hummingbird; Janssen; Kestrel Labs; Lilly; Mersana; Mirati Therapeutics; nalo therapeutics; Nuvalent, Inc.; OnKure; Puma Biotechnology; Ribon Therapeutics; Roche; Sanofi; Seagen; takeda; Turning Point Therapeutics
Research Funding - Inivata (Inst)
 
Byoung Chul Cho
Leadership - Interpark Bio; J Ints Bio
Stock and Other Ownership Interests - Bridgebio; Cyrus therapeutics; Gencurix; Interpark Bio; J INTS BIO; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - Abion; AstraZeneca; BeiGene; Blueprint medicines; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb; CJ bioscience; CureLogen; Cyrus therapeutics; GI Cell; Guardant Health; Hanmi; Imnewrun; inno.N; Janssen; Kanaph Therapeutics; Lilly; Medpacto; MSD; Novartis; Onegene Biotechnology; Ono Pharmaceutical; Oscotec; Pfizer; RandBio; Roche; Takeda; Yuhan
Research Funding - Abbvie; Abion; AstraZeneca; Bayer; Blueprint medicines; Boehringer Ingelheim; Bridgebio; CHA Bundang Medical Center; Champions Oncology; CJ bioscience; CJ Blossom Park; Cyrus Therapeutics; Dizal Pharma; Dong-A ST; Genexine; GI Cell; GI Innovation; Hanmi; Illumina; ImmuneOncia; Interpark Bio; J Ints Bio; Janssen; Kanaph therapeutics; LG Chem; Lilly; Mogam Biotechnology Research Institue; MSD; Novartis; Nuvalent, Inc.; Oncternal Therapeutics; Ono Pharmaceutical; Oscotec; Regeneron; Therapex; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology; Crown Bioscience; Imagen
Other Relationship - DAAN Biotherapeutics
 
Enriqueta Felip
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BerGenBio; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; F. Hoffmann LaRoche; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Sanofi; Takeda; Turning Point Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; F. Hoffmann LaRoche; Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; PeerVoice; Pfizer; Sanofi; Takeda; Touch Oncology
Research Funding - Merck (Inst); Merck KGaA (Inst)
Other Relationship - GRIFOLS
 
Koichi Goto
Honoraria - Amgen; Amgen; Amoy Diagnostics; AstraZeneca Japan; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health; Janssen; Life Technologies; Lilly Japan; Medpace; Merck; Novartis; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Bayer; Janssen; Lilly Japan; Medpace
Research Funding - Amgen (Inst); Amgen (Inst); Amgen Astellas BioPharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Eisai (Inst); Ignyta (Inst); Janssen (Inst); Kissei Pharmaceutical (Inst); Kyowa Kirin Co., Ltd. (Inst); Lilly Japan (Inst); Loxo (Inst); MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Inst); Merck (Inst); Merus (Inst); MSD K.K. (Inst); NEC Corporation (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shanghai HaiHe Pharmaceutical (Inst); Spectrum Pharmaceuticals (Inst); Sumitomo Dainippon Pharma Co., Ltd. (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Thermo Fisher Scientific (Inst); Turning Point Therapeutics (Inst)
 
Chia-Chi Lin
Honoraria - Daiichi Sankyo; Lilly; Novartis; Novartis; Roche
Consulting or Advisory Role - Abbvie; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; IMPAC Medical Systems; Novartis; PharmaEngine
Travel, Accommodations, Expenses - BeiGene; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; IMPAC Medical Systems; Lilly
 
Zofia Piotrowska
Consulting or Advisory Role - AstraZeneca; C4 Therapeutics; Cullinan Oncology; Daiichi Sankyo Europe GmbH; Janssen; Lilly; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); ARIAD/Takeda (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Cullinan Oncology (Inst); Daiichi Sankyo Europe GmbH (Inst); GlaxoSmithKline/Tesaro (Inst); GlaxoSmithKline/Tesaro (Inst); Janssen Oncology (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst)
(OPTIONAL) Uncompensated Relationships - AstraZeneca/MedImmune
 
David Planchard
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Janssen; Lilly; Merck; Novartis; PeerVoice; Pfizer; Prime Oncology; Roche; Samsung; Sanofi
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Janssen; Lilly; Merck; Novartis; PeerVoice; Pfizer; Prime Oncology; Roche; Samsung; Sanofi
Other Relationship - AstraZeneca (Inst)
 
Julia K. Rotow
Honoraria - AstraZeneca
Consulting or Advisory Role - Abbvie; AstraZeneca; Genentech; Gritstone Bio; Guardant Health; Janssen; Lilly; Sanofi/Regeneron; Takeda
Travel, Accommodations, Expenses - AstraZeneca
 
David R. Spigel
Leadership - ASCO (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Evidera (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Molecular Templates (Inst); Monte Rosa Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi/Aventis (Inst)
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Agios (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Apollomics (Inst); Arcus Biosciences (Inst); Arrys Therapeutics (Inst); Ascendis Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BIND Therapeutics (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Denovo Biopharma (Inst); Eisai (Inst); Elevation Oncology (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); Faeth Therapeutics (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Hutchison MediPharma (Inst); ImClone Systems (Inst); Incyte (Inst); Ipsen (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Kronos Bio (Inst); Lilly (Inst); Loxo (Inst); Lyell Immunopharma (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Molecular Templates (Inst); Monte Rosa Therapeutics (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Novocure (Inst); Peloton Therapeutics (Inst); PureTech (Inst); Razor Genomics (Inst); Repare Therapeutics (Inst); Rgenix (Inst); Seagan (Inst); Shenzhen Chipscreen Biosciences (Inst); Stemline Therapeutics (Inst); Synthekine (Inst); Taiho Oncology (Inst); Tango Therapeutics (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); Verastem (Inst); Zai Lab (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Novartis
 
Daniel Shao-Weng Tan
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; C4 Therapeutics; Loxo; Merck; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche
 
Tatsuya Yoshida
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo/UCB Japan; Lilly Japan; MSD Oncology; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Lilly Japan; MSD
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Blueprint Medicines; Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical; Ono Pharmaceutical (Inst); Takeda (Inst)
 
Anna Rachel Minchom
Honoraria - Bayer; Chugai Pharma; GlaxoSmithKline; Janssen; Merck; Novartis Pharmaceuticals UK Ltd.
Consulting or Advisory Role - Genmab; Janssen Oncology; Merck; Takeda
 
Adrianus De Langen
Consulting or Advisory Role - AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Merus (Inst); MSD Oncology (Inst); Roche (Inst)
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - Amgen; AstraZeneca; BeiGene; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Takeda
Consulting or Advisory Role - AstraZeneca; BeiGene; DaiichiSankyo; Janssen; Merck Serono; MSD; Novartis; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Haihe Biopharma (Inst); Lilly (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Takeda (Inst); Turning Point Therapeutics (Inst)
 
Alena Zalutskaya
Employment - Blueprint Medicines
Stock and Other Ownership Interests - Blueprint Medicines
 
Karen L. Reckamp
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Lilly; EMD Serono; Genentech; GlaxoSmithKline; Janssen Oncology; Lilly; Merck KGaA; Mirati Therapeutics; Seagen; Takeda
Research Funding - Blueprint Medicines; Calithera Biosciences (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst)